Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

STORY: Since launching its popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn.

Second, one of Novo Nordisk's leading pipeline candidates failed to knock things out of the park. The company is developing CagriSema as a weight management medicine. In December, Novo Nordisk ...

Weight loss leader Novo Nordisk has had a poor performance at ... trial results for its obesity and diabetes treatment CagriSema. The first big price fall came after the company released its ...

Novo Nordisk produces most of their drugs in Europe, which could make them subject to tariffs and margin pressures. Also, Cagrisema, their drug in Phase 2 development, achieved 22.7% of weight ...